GlassScriptPhysician profile
Diane M Williams
NPI 1598700767
$4,007.54
in general payments reported to CMS, 2019-2025
30 companies · $655 in 2025
The $655 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $47.35 · 2021: $157 · 2022: $398 · 2023: $968 · 2024: $1,079 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,680 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,680.16 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,554.32 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $318.60 | 2019-2025 | Tremfya, Stelara, Simponi |
| Phathom Pharmaceuticals, INC. | $219.93 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $182.95 | 2019-2025 | Entyvio |
| Pfizer INC. | $172.73 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $124.81 | 2019-2025 | |
| Novo Nordisk INC | $124.63 | 2019-2025 | Wegovy |
| Celgene Corporation | $116.05 | 2023-2024 | Zeposia |
| Olympus America INC. | $112.91 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.42 | 2022-2025 | Trulance, Xifaxan |
| Gilead Sciences, INC. | $100.59 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $100.36 | 2019-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $96.30 | 2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $77.42 | 2023-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $76.45 | 2023-2024 | Dupixent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $67.16 | 2019 | |
| Lilly USA, LLC | $57.65 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $56.33 | 2019-2022 | |
| Ardelyx, INC. | $50.12 | 2023-2025 | Ibsrela |
| Fresenius Kabi USA, LLC | $49.78 | 2023-2024 | Idacio |
| Ipsen Biopharmaceuticals, INC | $47.37 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $32.75 | 2024-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $25.70 | 2024 | Resmetirom |
| Aimmune Therapeutics, INC. | $25.62 | 2025 | Zenpep |
| Amgen INC. | $25.15 | 2021 | |
| Evoke Pharma, INC. | $22.35 | 2023 | Gimoti |
| Enterra Medical, INC. | $19.52 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.61 | 2019 | |
| Glaxosmithkline, LLC. | $13.98 | 2024 | Shingrix, Arexvy |
| Cook Medical LLC | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.